NMRA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Neumora Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice

Oct 30, 2026

8-K

Neumora Therapeutics Reports Q2 2026 Financial Results and Announces Leadership Changes

Aug 14, 2026

8-K

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results and Plans Clinical Advancement

Jul 27, 2026

8-K

Neumora Therapeutics Discontinues Navacaprant Development Following Phase 3 Trial Results

Jun 15, 2026

8-K

Neumora Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 29, 2026

8-K

Neumora Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

14,710,000 Shares

Sep 18, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 30, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 3, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Mar 3, 2025

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Mar 3, 2025

S-3ASR

SHELF | ATM | Offering amount: $300,000,000.00

Oct 1, 2024

S-8

Registration

Mar 7, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 16, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 11, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Aurora Daljit Singh (Reporting)

Aug 21, 2026

BERNS PAUL L (Reporting)

Aug 21, 2026

Duncan Jason (Reporting)

Aug 21, 2026

Milligan Michael Lee (Reporting)

Aug 21, 2026

Pinto Joshua (Reporting)

Aug 21, 2026

144

Form 144 - Report of proposed sale of securities

Aug 21, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 27, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 18, 2023

CORRESP

Form CORRESP - Correspondence

Sep 12, 2023

CORRESP

Form CORRESP - Correspondence

Sep 12, 2023

CORRESP

Form CORRESP - Correspondence

Aug 25, 2023

LETTER

Form UPLOAD - SEC-generated letter

Aug 17, 2023

Neumora Therapeutics, Inc. Common Stock NMRA · SEC Filings